Best Managed Healthcare Stocks To Invest In Right Now

U.S. stock-index futures increased, indicating the Standard & Poor’s 500 Index may extend a record in today’s shortened trading session, before economic reports next week.

Apple Inc. climbed 0.8 percent in early New York trading after a report showed the company sold three of every four smartphones in Japan last month. Archer-Daniels-Midland Co. rose 0.5 percent in European trading after Australia blocked a A$2.2 billion ($2 billion) takeover of GrainCorp Ltd.

S&P 500 futures expiring in December advanced 0.3 percent to 1,809.10 at 7:20 a.m. in New York. Dow Jones Industrial Average contracts added 51 points, or 0.3 percent, to 16,125. The S&P 500 climbed 27 percent this year, and the Dow gained 23 percent, after the Federal Reserve refrained from tapering its third round of economic stimulus.

“Investors are waiting for indications on when tapering may come,” said Ioan Smith, strategist at KCG Europe Ltd. “The minutes revealed a wide-ranging discussion of various policy scenarios and contingencies. It is still the case that there’s not enough sustained evidence to meet the taper criteria as soon as next month.”

Best Managed Healthcare Stocks To Invest In Right Now: Natural Grocers By Vitamin Cottage Inc (NGVC)

Natural Grocers by Vitamin Cottage, Inc., incorporated on April 9, 2012, is a specialty retailer of natural and organic groceries and dietary supplements. The Company operates within the natural products retail industry. The Company offers products and brands, including a selection of natural and organic food, dietary supplements, body care products, pet care products and books.

The Company offers its customers an average of approximately 18,000 store-keeping units (SKUs) of natural and organic products per store, including an average of approximately 7,000 SKU of dietary supplements. As of June 30, 2012, the Company operated 55 stores in 11 states, including Colorado, Idaho, Kansas, Missouri, Montana, Nebraska, New Mexico, Oklahoma, Texas, Utah and Wyoming, as well as a bulk food repackaging facility and distribution center in Colorado. The size of its stores varies from 5,000 selling square feet to 14,500 selling square feet, and a new store averages 9,500 selling square feet.

Advisors’ Opinion:

  • [By John Udovich]

    Large cap natural and organic foods supermarket giant Whole Foods Market, Inc (NASDAQ: WFM), otherwise known as “Whole Wallet”or “Whole Paycheck,” is not the only player in the natural or organics supermarket space for consumers and investors alike as mid cap Sprouts Farmers Market Inc (NASDAQ: SFM) and small caps Fairway Group Holdings Corp (NASDAQ: FWM) and Natural Grocers by Vitamin Cottage Inc (NYSE: NGVC) are also players in the space. It should be mentioned that Whole Foods Market is down 15.7% since the start of the year and has a downward trending technical chart, but shares are still up 13% over the past year, up 426.3% over the past five years and up 3,108.6% since January 1992.

  • [By John Udovich]

    Small cap Natural Grocers by Vitamin Cottage (NYSE: NGVC) and mid cap Sprouts Farmers Market Inc (NASDAQ: SFM) are taking aim at natural and organic foods supermarket giant Whole Foods Market (NASDAQ: WFM), but do either of these stocks have what it takes to take on the the king of organic retailing? Whole Foods Market was founded in Austin way back in 1978 by a twenty-five year old college dropout and a twenty-one year old at a time when there were only a handful of natural or organic supermarkets in the country. Today, Whole Foods Market has 364 stores in the United States, Canada and the United Kingdom – which are sometimes referred to as “Whole Wallet”or “Whole Paycheck” given how much it costs to shop there.

  • [By David Mamos]

    The Fresh Market Inc. (Nasdaq: TFM), Natural Grocers by Vitamin Cottage Inc. (NYSE: NGVC), and privately held Trader Joe’s are others crowding into the field.

Best Managed Healthcare Stocks To Invest In Right Now: Owens & Minor Inc.(OMI)

Owens & Minor, Inc., together with its subsidiaries, provides distribution, third-party logistics, and other supply-chain management services to healthcare providers and suppliers of medical and surgical products. Its services include logistics, supplier management, analytics inventory management, outsourced resource management, clinical supply management, and business process consulting. The company also offers various services comprising PANDAC, an operating room-focused inventory management program that helps healthcare providers to control suture and endo-mechanical inventory; SurgiTrack, a customizable surgical supply service that includes the assembly and delivery of surgical supplies in procedure-based totes; OMSolutions, a supply-chain consulting, customer technology, and resource management service; and WISDOM Gold, an Internet-based supply spend management, data normalization, and contract management solution. In addition, it provides Clinical Supply Solutions, a n inventory and contract management service; and Implant Purchase Manager, a technology-based service, as well as owns OM HealthCare Logistics, a customized third-party logistics and business process outsourcing service. Further, the company distributes medical and surgical supplies to the acute-care market. It serves federal government, including the U.S. department of defense; and alternate-site providers, such as ambulatory surgery centers, physicians? practices, clinics, home healthcare organizations, nursing homes, and rehabilitation facilities, as well as provides distribution and supply-chain management services that include third-party logistics and business process outsourcing services to manufacturers of medical and surgical products. Owens & Minor, Inc. was founded in 1882 and is headquartered in Mechanicsville, Virginia.

Advisors’ Opinion:

  • [By Chris Mydlo]

    Owens & Minor Inc. (OMI) is trading at a low P/S ratio of 0.20, near its 10-year low of 0.18. The company offers supply chain assistance to the providers of healthcare services and the manufacturers of healthcare products, supplies, and devices. It is held by 14 gurus we follow.

  • [By Marc Bastow]

    Third-party logistics services provider Owens & Minor (OMI) raised its quarterly dividend 4.2% to 25 cents per share, payable March 31 to shareholders of record as of March 17.
    OMI Dividend Yield: 2.82%

Best Managed Healthcare Stocks To Invest In Right Now: Julius Baer Gruppe AG (BAER)

Julius Baer Gruppe AG (the Group) is a Switzerland-based private banking group, with an exclusive focus on servicing and advising private clients and independent asset managers. The Group has a global presence with approximately 50 locations in more than 25 countries and jurisdictions. Julius Baer Gruppe AG was established through spin off from Julius Baer Holding AG’s businesses into two independent entities, namely the Company, together with its subsidiaries, comprising Bank Julius Baer & Co Ltd as its principal operating entity, and GAM Holding, together with its subsidiaries, comprising GAM and the Julius Baer-branded asset management business, which includes the private label funds business that formerly was part of Julius Baer Holding Ltd’s Bank Julius Baer segment. The Group diversifies its operations into geographical segments, including Switzerland, rest of Europe, Americas, and Asia and Other Countries. Advisors’ Opinion:

  • [By Corinne Gretler]

    Julius Baer Group Ltd. (BAER) rallied 5.7 percent to 42.04 francs. Switzerland’s third-biggest wealth manager said increased client trading boosted margins as it integrated Merrill Lynch businesses acquired from Bank of America Corp. last year. The gross margin, which reflects how much the bank makes in revenue on managed client assets, rose to 102 basis points in the first half, from 98 basis points in the year-earlier period.

Best Managed Healthcare Stocks To Invest In Right Now: Kirkland’s Inc.(KIRK)

Kirkland?s, Inc. operates as a specialty retailer of home decor and gifts in the United States. Its stores offer various merchandise, including framed art, mirrors, wall decor, candles and related items, lamps, decorative accessories, accent furniture, textiles, garden-related accessories, and artificial floral products. The company?s stores also provide an assortment of holiday merchandise during seasonal periods, as well as items suitable for gift-giving. It operates stores under the Kirkland?s, Kirkland?s Home, Kirkland?s Home Outlet, and Kirkland?s Outlet names. The company operates its stores in enclosed malls and various off-mall venues, including lifestyle centers, power strip centers, outlet centers, and freestanding locations. Kirkland?s, Inc. also sells its products through its Web site kirklands.com. As of March 08, 2012, it operated 299 stores in 30 states. The company was founded in 1966 and is based in Nashville, Tennessee.

Advisors’ Opinion:

  • [By Teresa Rivas]

    Other home furnishings retailers, including Bed, Bath & Beyond (BBBY), Restoration Hardware (RH) and Kirkland’s (KIRK) were trading down in afternoon trading.

  • [By Laura Brodbeck]

    Thursday

    Earnings Expected From: AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), Kirkland’s, Inc (NASDAQ: KIRK), Dollar General Corporation (NYSE: DG), Stein Mart, Inc. (SMRT: NASDAQ), Mattress Firm Holding Corp. (NASDAQ: MRFM), SeaWorld Entertainment (NYSE: SEAS), Vaalco Energy Inc (NYSE: EGY) Economic Releases Expected: Chinese retail sales, French CPI, Brazilian retail sales, US retail sales, Japanese industrial production

    Friday

  • [By Seth Jayson]

    Margins matter. The more Kirkland’s (Nasdaq: KIRK  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That’s why we check up on margins at least once a quarter in this series. I’m looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Kirkland’s competitive position could be.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Kirkland’s (Nasdaq: KIRK  ) , whose recent revenue and earnings are plotted below.

Best Managed Healthcare Stocks To Invest In Right Now: Cantel Medical Corp. (CMN)

Cantel Medical Corp. provides infection prevention and control products and services in the healthcare market. Its Endoscopy segment offers medical device reprocessing systems, disinfectants, detergents, and other supplies that are used to disinfect flexible endoscopes; and disposable infection control products for cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures. Its Water Purification and Filtration segment offers water purification equipment and services, filtration and separation products, and disinfectants for medical, pharmaceutical, biotech, beverage, and commercial industrial markets. This segment also offers hollow fiber membrane filtration and separation technologies for medical applications; and sterilants, disinfectants, and decontamination services used in various applications for infection prevention and control. The company’s Healthcare Disposables segment offers single-use infection prevention and control healthca re products, including face masks, sterilization pouches, towels and bibs, tray covers, saliva ejectors, germicidal wipes, plastic cups, and disinfectants used principally in the dental market; and biological and chemical indicators for sterility assurance monitoring services in the acute-care, alternate-care, and dental markets. Its Dialysis segment offers medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates, and other supplies for renal dialysis. The company’s Specialty Packaging segment offers specialty packaging and thermal control products, as well as related compliance training for the transportation of infectious and biological specimens and thermally sensitive pharmaceutical, medical, and other products. Cantel Medical Corp. sells its products through its direct distribution network in the United States; and directly and through third-party distributors internationally. The company was founded in 1963 and is based in Little Falls, N e w Jersey.

Advisors’ Opinion:

  • [By Marc Bastow]

    Infection protection and control company Cantel Medical (CMN) raised its semiannual dividend 21.6% to 4.5 cents per share, payable Jan. 31, 2014, to shareholders of record as of Jan. 17.
    CMN Dividend Yield: 0.26%

Best Managed Healthcare Stocks To Invest In Right Now: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquir ed Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufactur ing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatm ent of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THA LOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to N ovartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company’s pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company’s oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company’s new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis a nd a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company’s research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn’s disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to de velop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors’ Opinion:

  • [By Ben Levisohn]

    Celgene (CELG) was on the receiving end of an upgrade today, but the upside has been limited as the biotech sector continues to sell off.

    Shares of Celgene gained 0.6% to $142.06 today, even as Amgen (AMGN) dropped 2% to 111.41, Biogen (BIIB) fell 3.1% to $285.81 and the SPDR S&P Biotech ETF (XBI) declined 3.9% to $124.37, extending its losing streak to three days. Gilead Sciences (GILD) dipped 0.2% to $73.90, ending a nine-day winning streak

    In a report titled “It’s Time…We Think,” Piper Jaffray’s Joshua Schimmer and team explain why they raised their rating on Celgene:

    The biotech sector has cooled off significantly over the past couple of months. Even a crushing EPS beat by [Gilead] barely moved that stock. Growth in general has come under pressure, and we are cognizant that high-multiple stocks may struggle to perform. While [Celgene] can’t yet be considered a “value” stock trading at a 2014 P/E multiple of 20x, it’s 20%+ sustainable EPS CAGR means it will eventually either become a value stock or see multiple stabilization with share performance driven by organic EPS growth…

    We believe the valuation now reflects a conservative 2024 Revlimid patent expiry and excludes meaningful contribution from the advancing pipeline. As such, we are less concerned with Revlimid’s May 15 Markman hearing outcome for the Revlimid polymorph patents since we believe a settlement somewhere between the method of use (2024) and polymorph (2027) dates is the most likely outcome regardless. Such a settlement could come this year and act as a potent catalyst to lift shares out of their doldrums.  [Celgene] is attuned to delivering shareholder value and we believe will fight aggressively to lift the Revlimid polymorph patent overhang and deliver sustainable EPS growth. We are upgrading from Neutral to OW…

    At least the market noticed, even if the gain wasn’t much.<

  • [By Todd Campbell]

    Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights Celgene (NASDAQ: CELG  ) , AbbVie (NYSE: ABBV  ) , and Gilead (NASDAQ: GILD  ) .

  • [By Ben Levisohn]

    Maybe, notes RBC Capital Markets’ Michael Yee and John Chung, who look at the free-cash-flow yield for Gilead Sciences (GILD) and Celgene (CELG).

  • [By Ben Levisohn]

    After rallying yesterday, biotech stocks are getting pounded, as Gilead (GILD), Amgen (AMGN) and Celgene (CELG) slide today.

    The iShares Nasdaq Biotech ETF (IBB) fell 5.6% to $221.89 today, while the SPDR S&P Biotechnology ETF (XBI) dropped 6.5% to $129.79. Gilead Sciences fell 7.3% to $65.48, Amgen declined 4.9% to $114.11 and Celgene finished down 5% at $139.98.

Best Managed Healthcare Stocks To Invest In Right Now: RWE AG (RWE)

RWE AG is a Germany-based electricity and gas company. It diversifies its activities into seven divisions: Germany, which consists of the Power Generation and Sales and Distribution Networks business area; Netherlands/Belgium; Great Britain; The Central Eastern and South Eastern Europe; Renewables; Upstream Gas and Oil, and Trading/Gas Midstream. Under the Netherlands/Belgium division it reports on wholly owned Essent, which provides gas, electricity, heat and energy services. The United Kingdom division represents RWE npower; The Central Eastern and South Eastern Europe division covers its subsidiaries in Poland, Hungary, the Czech Republic, Turkey and Slovakia. The Renewables division comprises all of the activities of RWE Innogy, which specializes in electricity and heat generation from renewables. The Upstream Gas & Oil division produces gas and oil through RWE Dea. The Trading/Gas Midstream division encompasses energy trading, gas midstream activities, and sales to Germa n clients. Advisors’ Opinion:

  • [By Jonathan Morgan]

    RWE AG (RWE), Germany’s second-largest utility, slipped 2.4 percent after RBC Capital Markets cut its recommendation on the stock. Lufthansa followed its European peers higher, recovering some of its Aug. 2 selloff. Xing AG (O1BC), the business social network, jumped the most since October as Deutsche Bank AG (DBK) upgraded its rating on the shares.

  • [By Jonathan Morgan]

    RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.

Best Managed Healthcare Stocks To Invest In Right Now: Becton Dickinson and Company(BDX)

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company?s BD Medical segment produces medical devices that are used in various healthcare settings. This segment?s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes, pen needles, and other drugs to treat diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Diagnostics segment provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment?s products consist of integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. The company?s BD Biosciences segment produces research and clinical tools that facilitate the study of cells and their components. This segment?s products comprise fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It markets its products through independent distribution channels and independent sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Advisors’ Opinion:

  • [By MONEYMORNING.COM]

    My preference is definitely for “global challengers” with strong cash flow, experienced management, and powerful brands in the meantime. Examples include ABB Ltd (ADR) (NYSE: ABB), Becton Dickinson and Co. (NYSE: BDX), and American Water Works Company Inc. (NYSE: AWK) that are drawn from our Money Map Report recommendations. Not only are these companies and others like them tapped into global money flows that continue unabated, but these types of companies can actually benefit from rising rates rather than get crushed by them. Remember, earnings… earnings… earnings!

  • [By Ingrid Hendershot]

    Becton Dickinson (BDX) yields 1.9% and has raised its dividend for 42 years.

    Brown-Forman (BF-B) yields 1.6% and has raised its dividend for 30 years.